- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pharmacy-Driven Challenges
Panelists discuss how pharmacy-related delays and limited escalation practices widen LDL-C management gaps.
EP: 1.Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia
EP: 2.Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap
EP: 3.Pharmacy-Driven Challenges
EP: 4.Real-World Insights and PROMPT-LIPID
EP: 5.Social Determinants of Health
EP: 6.The 2013 Guideline Shift
EP: 7.Unintended Consequences of Metric Changes
EP: 8.Reinstating LDL-C Targets
EP: 9.International LDL Thresholds
EP: 10.Nonstatin Therapy Decisions
EP: 11.PCSK9 Inhibitor Underuse
EP: 12.Payer and Prior Authorization Barriers
EP: 13.Adherence and Persistence
EP: 14.Cumulative LDL-C Exposure
EP: 15.Economic Burden and Systemwide Strategies
Panelists discuss how pharmacy-driven barriers, including delayed statin initiation and failure to escalate therapy, contribute to the widening low-density lipoprotein cholesterol (LDL-C) treatment gap. Many patients do not receive statins promptly after diagnosis, and follow-up titration or add-on therapy often lags.
They note that pharmacists are well-positioned to intervene but face formulary restrictions, lack of collaborative authority, and communication barriers with prescribers. The pharmacy pipeline’s role in ensuring timely medication access is critical but underutilized.
Panelists advocate for enhanced pharmacist-led protocols, real-time prescription monitoring, and payer reforms to streamline therapy initiation and intensification.
